Suchergebnisse - "Osinusi, Anu"

PubPharm (133)

1

Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection

enthalten in: Journal of pediatric gastroenterology and nutrition | 2024

von Jonas, M. | Romero, R. | Rosenthal, P. | +20

2

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants

enthalten in: Clinical and translational science | 2023

von Humeniuk, R. | Juneja, K. | Chen, S. | +13

3

Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

enthalten in: The American journal of gastroenterology | 2023

von Chan, H. | Buti, M. | Lim, Y. | +21

4

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

enthalten in: The New England journal of medicine | 2023

von Wedemeyer, H. | Aleman, S. | Brunetto, M. | +40

CommentIn: N Engl J Med. 2023 Sep 28;389(13):1247-1248. - PMID 37754293

5

The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies : A pooled safety analysis

enthalten in: Journal of viral hepatitis | 2023

von Jacobson, I. | Bourgeois, S. | Mathurin, P. | +9

6

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups : Treatment Effect Heterogeneity in PINETREE Study

enthalten in: Infectious diseases and therapy | 2023

von Brown, S. | Katz, M. | Ginde, A. | +15

7

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study

enthalten in: Infectious diseases and therapy | 2023

von Brown, S. | Katz, M. | Ginde, A. | +15

8

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

enthalten in: ResearchSquare.com | 2023

von Pan, D. | Odorizzi, P. | Schoenichen, A. | +7

9

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

enthalten in: Communications medicine | 2023

von Pan, D. | Odorizzi, P. | Schoenichen, A. | +7

10

The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL1, 2 and 3 studies : A pooled safety analysis

enthalten in: Journal of Viral Hepatitis | 2023

von Jacobson, I. | Bourgeois, S. | Mathurin, P. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]